SCHEMBL5771314

SCHEMBL5771314

CCOC(=O)c1conc1-c1ccc(F)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD2 Q15562 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
NPC1 O15118 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTPRC P08575 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPA Q15257 1/20 0.41
HSD17B10 Q99714 2/20 0.41
JAK2 O60674 2/20 0.41
JAK3 P52333 2/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
GCGR P47871 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5773232 0.91 TEAD2 (0.46) TEAD2SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL5774923 0.89 TEAD2 (0.54) TEAD2SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL5769963 0.86 MEN1 (0.41) TEAD2SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL2929533 0.85 SMN1; SMN2 (0.52) SMN1; SMN2KDM4EALDH1A1HPGDNPC1
SCHEMBL11395576 0.83 JAK2 (0.55) SMN1; SMN2KDM4EALDH1A1HPGDKMT2A
SCHEMBL1776614 0.82 KDM4E (0.51) SMN1; SMN2KDM4EALDH1A1HPGDNPC1
SCHEMBL3978092 0.81 JAK2 (0.55) SMN1; SMN2KDM4EALDH1A1HPGDMEN1
SCHEMBL8163709 0.78 TSHR (0.44) SMN1; SMN2KDM4EALDH1A1HPGDATM
SCHEMBL5772148 0.77 ALDH1A1 (0.53) SMN1; SMN2KDM4EALDH1A1HPGDNPC1
SCHEMBL11396935 0.77 ALDH1A1 (0.56) SMN1; SMN2KDM4EALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR TEAD2 4577/4885SMN1; SMN2 3383/4885KDM4E 3953/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 TEAD2 4486/4885SMN1; SMN2 2449/4885KDM4E 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.